Progress in Cardiovascular Diseases
Volume 53, Issue 2 , Pages 164-172 , September 2010

Prolonged QTc Interval in Cancer Therapeutic Drug Development: Defining Arrhythmic Risk in Malignancy

References 

  1. Vertex Pharmaceuticals press releases available at: http://investors.vrtx.com/releaseDetail.cfm?releaseid=325650, 2008 and http://investors.vrtx.com/releasedetail.cfm?ReleaseID=276543, 2007. Last accessed July 22, 2010.
  2. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use . The clinical evaluation of QT/QTc prolongation and pro-arrhythmic potential for non-antiarrhythmic drugs: E14. Geneva, Switzerland: International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use; 2005;Available at: http://www.ich.org/LOB/media/MEDIA1476.pdfLast accessed July 22, 2010
  3. Darpo B. Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes. Eur Heart J Suppl. 2003;3K:K70–K80
  4. Whellan DJ, Green CL, Piccini JP, et al. QT as a safety biomarker in drug development. Clin Pharmacol Ther. 2009;86:101–104
  5. HaverKamp W, Breithardt G, Camm JA, et al. Potential for QT prolongation and pro-arrhythmia by non–anti-arrhythmic drugs: clinical and regulatory implications report on a Policy Conference of the European Society of Cardiology. Cardiovasc Res. 2000;47:219–223
  6. Moss AJ. QT interval and torsades de pointes. Drug Saf. 1999;21(Suppl):5–10
  7. Vitola J, Vukanovic J, Roden DM. Cisapride-induced torsades de pointes. J Cardiovasc Electrophysiol. 1998;9:1109–1113
  8. Strevel EL, Ing DJ, Su LL. Molecularly targeted oncology therapeutics and prolongation of the QT interval. J Clin Oncol. 2007;25:3262–3371
  9. Fingert H, Varterasain M. Safety biomarkers and the clinical development of oncology therapeutics: considerations for cardiovascular risk and safety management. AAPS J. 2006;8(article 10):E89–E94
  10. Bednar MM, Harrigan EP, Anziano RJ, et al. The QT interval. Prog Cardiovasc Dis. 2001;43(No 5 suppl):1–45
  11. Zehender M, Hohnloser S, Just H. QT-interval prolonging drugs: mechanisms and clinical relevance of their arrhythmic hazards. Cardiovasc Drugs Ther. 1991;5:515–530
  12. Molnar J, Zhang F, Weiss J, et al. Diurnal pattern of QTc interval: how long is prolonged? Possible relation to circadian triggers of cardiovascular events. J Am Coll Cardiol. 1996;27:76–83
  13. Agin MA, Kazierad DJ, Abel R, et al. Assessing QT variability in normal volunteers. Proc Am Coll Clin Pathol. 2003;
  14. Priori SG, Schwartz PJ, Napolitano C, et al. Risk stratification in the long-QT syndrome. N Engl J Med. 2003;348:1866–1874
  15. Andersom ME, Al-Khatib SM, Roden DM, et al. Cardiac repolarization: current knowledge, critical gaps, and new approaches to drug development and patient management. Am Heart J. 2002;144:769–781
  16. Redfern WS, Carlsson L, Davis AS, et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsades de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res. 2003;58:32–45
  17. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350:1013–1022
  18. Yang T, Snyders D, Roden DM. Drug block of IKr: model systems and relevance to human arrhythmias. J Cardiovasc Pharmacol. 2001;38:737–744
  19. Barbey JT, Pezzullo JC, Saignet SL. Effect of arsenic trioxide on QT interval in patients with advanced malignancies. J Clin Oncol. 2003;21:3609–3615
  20. Varterasian M, Meyer M, Fingert H, et al. Baseline heart rate-corrected QT and eligibility for clinical trials in oncology. J Clin Oncol. 2003;21:3378–3379
  21. Ahmad K, Dorian P. Drug-induced QT prolongation and proarrhythmia: an inevitable link?. Europace-Eur Soc Cardiol. 2007;iv16–iv22
  22. Floyd JD, Nguyen DT, Lobins RL, et al. Cardiotoxicity of cancer therapy. J Clin Oncol. 2005;23:7685–7696
  23. DePonti F, Poluzzi E, Montanaro N. QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience. Eur J Clin Pharmacol. 2000;56:1–18
  24. Sarapa N, Britto MR. Challenges of characterizing proarrhythmic risk due to QTc prolongation induced by nonadjuvant anticancer agents. Expert Opin Drug Saf. 2008;7:305–318
  25. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use . The non-clinical evaluation of the potential for delayed ventricular repolarization (Qt interval prolongation) by human pharmaceuticals: S7B. Geneva, Switzerland: International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use; 2005;Available at: http://www.ich.org/LOB/media/MEDIA2192.pdfLast accessed July 22, 2010.
  26. Rock EP, Finkle J, Fingert HJ, et al. Assessing proarrhythmic potential of drugs when optimal studies are infeasible. Am Heart J. 2009;157:827–836
  27. Shah RR. If a drug deemed “safe” in nonclinical tests subsequently prolongs QT in phase 1 studies, how can its sponsor convince regulators to allow development to proceed?. Pharmacol Ther. 2008;119:215–221
  28. Garnett CE, Beasley N, Bhattaram VA, et al. Concentration-QT relationships play a key role in evaluation of proarrhythmic risk during regulatory review. J Clin Pharmacol. 2008;48:13–18
  29. Kummar S, Kinders R, Rubinstein L, et al. Compressing drug development timelines in oncology using phase “0” trials. Nat Rev Cancer. 2007;7:131–139
  30. Arsenic trioxide prescribing information available at: http://www.trisenox.com/490-Trisenox-Prescibing-Info.aspx. Last accessed July 22, 2010.
  31. Agrawal M, Grady C, Fairclough DL, et al. Patients' decision-making process regarding participation in phase I oncology research. J Clin Oncol. 2006;24:4479–4484
  32. QTc prolonging agents available at: http://www.qtdrugs.org. Last accessed July 22, 2010.
  33. Romidepsin prescribing information available at: www.accessdata.fda.gov/drugsatfda_docs/label/2009/022393lbl.pdf. Last accessed July 22, 2010.
  34. Bates SE, Rosing DR, Fofo T, et al. Challenges of evaluating cardiac effects of anticancer agents. Clin Cancer Res. 2006;12:3871–3873
  35. Piekarz RL, Frye AR, Wright JJ, et al. Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clin Cancer Res. 2006;12:3762–3773
  36. Fitzgerald PT, Ackerman MJ. Drug-induced torsades de pointes: evolving role of pharmacogenomics. Heart Rhythm. 2005;2:S30–S37

 Statement of Conflict of Interest: see page 171.

 Address reprint requests to Joanna Brell, MD, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, 6130 Executive Blvd. EPN 2017, Bethesda, MD 20892.

PII: S0033-0620(10)00091-5

doi: 10.1016/j.pcad.2010.05.005

Progress in Cardiovascular Diseases
Volume 53, Issue 2 , Pages 164-172 , September 2010

Article Tools

* Image Usage & Resolution